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Abstract
Background: There is little information on the effectiveness of modern compared to traditional
malaria treatment from the rural areas of Africa.
Methods: Follow-up of 402 episodes of clinical malaria among pre-school children in Nouna
Health District, northwestern Burkina Faso. The exposure of interest was the type of treatment
(chloroquine versus traditional); the outcome was clinical response to treatment.
Results: Out of the 402 observed malaria episodes, 87% were treated with chloroquine and 13%
with traditional remedies. Overall, community effectiveness was 67% with chloroquine and 54%
with traditional treatment. Chloroquine effectiveness was associated with age and ethnicity. An
additional interview survey demonstrated wide variations in the dosages of chloroquine given to
young children in this community.
Conclusions: The effectiveness of chloroquine, when used within the community, was significantly
lower in this study than its known efficacy in the study area. This concerns, in particular, the very
young children. These findings demonstrate the need for better education of parents about correct
dosage of first-line malaria drugs, and for particular attention in the treatment of very young
children.
Introduction
It has been estimated that at least one million annual
malaria deaths occur among young children in rural sub-
Saharan Africa (SSA). Most of these deaths are in areas
with little access to health services [1-4]. Under such cir-
cumstances, home treatment with chloroquine, antipyret-
ics and traditional remedies is the most frequent response
of caretakers to fever episodes in children [5]. There is also
increasing evidence that improved home management of
malaria in young children of SSA can be effective [6,7].
The situation is now complicated by the increasing resist-
ance of Plasmodium falciparum to chloroquine in most
SSA countries [8]. Moreover, compared to the efficacy
under trial conditions, the community effectiveness (the
drug efficacy under real life conditions) of malaria treat-
ment is significantly lower [9]. Chloroquine has been
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used in Burkina Faso for decades and reported clinical fail-
ure rates in children with uncomplicated malaria were
around 5% in the early 1990s [10]. However, data from a
more recent study on the efficacy of chloroquine in a rep-
resentative sample of villages in the Nouna Health District
in north-western Burkina Faso demonstrated a clinical
failure rate of 10% in young children [11]. Nevertheless,
chloroquine has remained the official first-line treatment
for uncomplicated malaria in Burkina Faso until today.
Traditional treatment for malaria is very common, partic-
ularly in the rural areas of SSA, but only few data exist
regarding the efficacy of such treatments [5,12]. In rural
north-western Burkina Faso, treatment of uncomplicated
malaria usually comprises a combination of modern and
traditional methods. Chloroquine and antipyretics, often
combined with traditional treatments, are the most com-
mon community-based treatment regimens for young
children during fever episodes [4]. Traditional treatments
usually comprise oral and/or skin applications of extracts
from eucalyptus plants, acacia, citronella, papaya, guava
and the neem tree [13].
This paper reports on the community effectiveness of
chloroquine compared to traditional remedies in the
treatment of uncomplicated falciparum malaria in young
children of rural Burkina Faso.
Methods
Study area
The study was conducted in the rural part of the research
zone of the Centre de Recherche en Santé de Nouna
(CRSN), in Nouna Health District, north-western Burkina
Faso. The CRSN study zone comprises 41 villages and
Nouna town, with a total population of 55,000. The
Nouna area is a dry orchard savanna, populated by sub-
sistance farmers of different ethnic groups. There is a short
rainy season which usually lasts from June until October.
Malaria is holoendemic but highly seasonal in the study
area [14]. Formal health services in the CRSN study zone
consist of four village-based health centres and the district
hospital in Nouna town [4].
Study design
This is an observational study at the community level.
Data for this study were extracted from the database of a
trial on the effects of zinc supplementation on malaria
morbidity conducted in the Nouna area in 1999 [14].
During this trial, 709 children aged 6–31 months at
enrollment in June 1999 were recruited from 18 villages
of Nouna Health District. Study children were followed
up until December 1999.
Field methods for data collection have already been
described [14]. In brief, the children in the study were reg-
ularly visited by village-based field staff for temperature
measurement and malaria slide preparation from finger-
prick blood in case of fever over the main malaria trans-
mission period (June to December). If fever persisted or
recurred, another blood slide was prepared at least one
week after the start of the febrile episode. If children were
found to have fever or other obvious illness, their caretak-
ers were advised by the field staff to use chloroquine for
febrile episodes or to seek diagnosis and treatment at the
next governmental health centre. Children found ill dur-
ing four cross-sectional surveys were treated appropriately
by the study physician or referred to Nouna hospital,
where they were treated free of charge.
All relevant signs and symptoms manifested by the chil-
dren were recorded on a standard questionnaire during
regular visits of field staff. Moreover, a comprehensive
questionnaire was filled in for each disease episode which
included information on specific signs and symptoms as
well as place, time and type of treatment received. No spe-
cific information was recorded on the dosage of chloro-
quine and on the type of traditional remedies given to the
study group.
For this study, only children with a diagnosis of falci-
parum malaria, defined as an axillary temperature of
≥37.5°C together with a density of ≥5,000 P. falciparum
parasites per µl of blood were considered. Inclusion crite-
ria were falciparum malaria treated with chloroquine
(with or without antipyretics) but without traditional
remedies (group CQ), or with traditional remedies only
(group TRAD). Exclusion criteria were a history of febrile
illness during the previous four weeks, malaria treatment
during the previous four weeks, any treatment with
another antimalarial drug during follow up, and missing
temperature measurements during the two-weeks follow
up period. Multiple episodes of malaria in individual chil-
dren were considered to be independent with regard to
treatment choice [4].
To evaluate treatment outcome, a modified definition of
the WHO protocol for assessment of therapeutic efficacy
of antimalarial drugs in areas with intense transmission
was used [15]. Treatment failure (TF) was defined as
development of severe malaria on day 1–14 or fever recur-
rence (axillary temperature ≥37.5°C) on day 3–14. Ade-
quate clinical response (AR) was defined as the absence of
fever on day 3–14, without meeting any of the criteria of
TF.
Chloroquine dosage survey
To retrospectively estimate the chloroquine dosages usu-
ally given to febrile young children in the study area, 55
individual interviews with randomly selected mothers of
young children from three villages in the study area wereMalaria Journal 2004, 3:36 http://www.malariajournal.com/content/3/1/36
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conducted during a malaria survey at the end of the 2001
rainy season. The villages were purposely selected to rep-
resent the rural study population in its socio-cultural,
demographic and geographical diversity. Questions con-
cerned the kind of treatment (western and/or traditional)
and the dosages of western drugs used during treatment of
the last febrile episode of survey children, the current
availability of chloroquine in the household and the ori-
gin of chloroquine drugs. The weight of children was
measured with a Salter hanging spring scale.
Laboratory procedures
Blood films were kept in closed slide boxes until they were
transported to Nouna (two to three times per week). They
were Giemsa-stained at the Nouna hospital laboratory
and transported afterwards to the Centre National de
Recherche et de Formation sur le Paludisme (CNRFP) in
Ouagadougou for reading. All films were examined by
two experienced laboratory technicians using a ×100 oil
immersion lens and ×10 eyepieces. In case of significant
discrepancy between the results of the two technicians,
blood slides were read by a third investigator. Blood films
were analysed for the species-specific parasite density per
µl by counting against 500 white blood cells and multi-
plying by sixteen (assuming 8,000 white blood cells per µl
of blood). Slides were declared negative if no parasites
were seen in 400 fields on the thick film.
Statistical analysis
Data were entered at the data management department of
the CRSN into a data bank (Microsoft Access, version 97).
All questionnaires were checked by supervisors before
computer entry. Parasitological data were entered into
EpiInfo (version 6.0) at the CNRFP, and the data were
transferred to the CRSN. All data were checked for range
and consistency before data entry.
The outcome of malaria episodes (AR vs. TF) was assessed
dependent on the treatment given by the caretakers. Epi-
sodes in which the child had received at least one dose of
chloroquine were grouped in the treatment group CQ,
and episodes in which caretakers had given only tradi-
tional treatment in the treatment group TRAD. The
hypothesis was tested that the samples in the CQ and the
TRAD treatment groups were from populations with the
same distribution of baseline variables using the Wil-
coxon ranksum test for continuous variables and the chi-
squared test for categorical variables. Community effec-
tiveness of treatment with chloroquine was assessed both
by intention to treat (i.e. adherence to advice by the field
workers to give chloroquine) and considering only those
cases who actually complied. A stratified analysis by age
bands was started, assuming that age would be an impor-
tant determinant of treatment outcome. Logistic regres-
sion modelling was then used to control for differences in
the distribution of baseline characteristics such as age, sex
and parasite density in the two treatment groups. Stata 7.0
statistical software was used for all calculations.
Ethical aspects
Approval for the RCT from which the data used were
drawn was granted by the Ethical Committee of the Hei-
delberg University Medical School and the Ministry of
Health in Burkina Faso.
Results
Follow-up study
A total of 330 children (175 boys and 155 girls), who con-
tributed 402 episodes of falciparum malaria, were fol-
lowed up. Most of the episodes (65.7%) occurred between
August and October (Table 1).
In 350 (87.1%) of the episodes, the child had received at
least one dose of chloroquine (treatment group CQ); in
52 episodes (12.9%), the caretakers had given only tradi-
tional treatment (treatment group TRAD). Table 2 shows
the distribution of baseline characteristics in the two treat-
ment groups. The median parasite density was signifi-
cantly lower in the TRAD group (p = 0.001), but diarrhoea
was observed in a larger proportion of episodes in this
group than in the CQ group (p = 0.04). In the Bwaba eth-
nic group, 33.3% of malaria episodes had been treated
with traditional treatment, compared to 8.7% in the other
ethnic groups (p < 0.0001).
The caretakers had been advised to give chloroquine to all
children participating in this study. Compliance with this
advice, stratified by age group, is shown in Table 3. Com-
pliance was independent of sex (data not shown), except
in the age group 15–21 months, in which 98.2% of epi-
sodes in girls, but only 86.8% of episodes in boys, were
treated with chloroquine (p = 0.02). Community effec-
tiveness as a result of following the advice to give chloro-
quine, measured by the proportion of episodes in which
the child had an AR was 64.9% (95% CI: 60.0–69.6%).
This proportion did not increase appreciably when we
restricted the analysis to episodes in which the child had
actually received chloroquine (Table 3). In the TRAD
group, children had an AR in 53.9% of the episodes. Our
study did not have sufficient power to show a difference
between the TRAD and the CQ groups as small as the one
observed (-11%) at the 5% significance level. In the CQ
group, outcome was strongly and positively associated
with age, as demonstrated by the chi-squared test for lin-
ear trend (p = 0.014). A comparable result was not shown
in the TRAD group, possibly because of small case
numbers.
The crude odds ratio for TF in the CQ group vs. the TRAD
group was 0.59 with a 95% confidence interval thatMalaria Journal 2004, 3:36 http://www.malariajournal.com/content/3/1/36
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Table 1: Distribution of febrile episodes by treatment type over the main malaria transmission period in young children of rural Burkina 
Faso
Month
7/99 8/99 9/99 10/99 11/99 total
Group CQ 25 126 108 75 16 350
Group TRAD 1 15 15 19 2 52
Total 26 141 123 94 18 402
Table 2: Baseline characteristics of malaria episodes in study children in rural Burkina Faso
Group CQ (n = 350) Group TRAD (n = 52) p-value *
Male/female 183/167 30/22 0.47
Median age, range (months) 20 (8 – 35) 19 (9 – 33) 0.36
Median parasite density/µl, D0 Range 26 220 
5000 – 1 140 000
16 352 
5000 – 86 656
0.001
Median temperature D0 (°C) 38.2 38.2 0.72
Diarrhoea D0 (%) 64/350 (18.3) 16/52 (30.8) 0.04
Vomiting D0 (%) 39/350 (11.1) 3/52 (5.8) 0.24
Ethnicity <0.0001
Marka 180 16
Mossi 72 8
Bwaba 46 23
Peulh 44 5
Others 8 0
* Chi-squared test for categorical variables, ranksum test for continuous variables
Group CQ: received at least one dose of chloroquine
Group TRAD: received only traditional treatment
D0: Day of onset of malaria episode
Table 3: Compliance with treatment and outcome of treatment, stratified by age group
Compliance Outcome of treatment
Age group CQ given n (%) AR, total n (%) AR, CQ group n (%) AR, TRAD group n (%)
8 – 14 months 87 (81.3) 58 (54.2) 49 (56.3) 9 (45.0)
15 – 21 months 121 (91.7) 89 (67.4) 83 (68.6) 6 (54.6)
22 – 28 months 86 (87.8) 63 (64.3) 57 (66.3) 6 (50.0)
29 – 35 months 56 (86.2) 51 (78.5) 44 (78.6) 7 (77.7)
Total 350 (87.1) 261 (64.9) 233 (66.6) 28 (53.9)
CI a - 60.0 – 69.6% 61.4 – 71.5% 39.5 – 67.8%
p-value 0.13 b 0.004 c 0.014 c 0.17 c
a CI: Binomial exact 95% confidence interval
b p-value: Chi-squared test for heterogeneity (within each column)
c p-value trend: Chi-squared test for linear trend (within each column)
CQ group: Received at least one dose of chloroquine
AR: Adeaquate clinical responseMalaria Journal 2004, 3:36 http://www.malariajournal.com/content/3/1/36
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included unity (Model 1 in Table 4). Logistic regression
modelling was used to assess the degree to which the
observed advantage of chloroquine treatment over tradi-
tional treatment was due to a different distribution of
baseline characteristics in the two treatment groups. Inclu-
sion of the variables age group (with four seven-month
age bands) and sex (Model 2 in Table 4), as well as para-
site density (log-transformed and grouped in three bands)
and diarrhoea on day 0 (Model 3 in Table 4) did not
change the odds ratio much; if there was any advantage of
chloroquine over traditional treatment it was slightly
attenuated. However, removing all episodes among chil-
dren of the Bwaba ethnic group from the analysis
decreased the odds ratio, and the corresponding confi-
dence interval no longer included unity (Model 4 in Table
4). This means that in the other ethnic groups, chloro-
quine treatment carried only 0.43 (95% CI: 0.19–0.91)
times the odds of treatment failure of traditional treat-
ment and thus conveyed a significant advantage.
Table 2 already showed evidence of an interaction
between treatment pattern and ethnic group. Therefore, a
subgroup analysis was done in which additional differ-
ences between the Bwaba and the other ethnic groups
were found. First, among the other ethnic groups, children
who received chloroquine had a significantly higher log-
transformed mean parasite density than those who
received traditional treatment (p = 0.002). The difference
in parasite density was smaller and not significant among
the Bwaba (p = 0.26). Secondly, treatment outcome was
not significantly associated with age group among the
Bwaba, while it was so among the other ethnic groups. In
Model 4, an increase in age by one age band (equivalent
to seven months) was associated with an almost 30%
reduction in the odds of treatment failure (p = 0.004) after
control for treatment type, sex, parasite density and diar-
rhoea on day 0 (also see Table 3). With a number of
important factors determining treatment type and/or out-
come varying by ethnic group, the stratified analyses were
warranted.
Chloroquine dosage survey
A total of 55 mothers participated in the survey with 28
girls and 27 boys aged 3–27 months (median: 14
months). During the most recent fever episodes of respec-
tive children, home treatment with chloroquine was
reported in 32/55 (58%) (8/32 in combination with para-
cetamol and 1/32 in combination with traditional treat-
ment), treatment at the local health centre in 15/55
(27%), traditional treatment in 6/55 (11%), and only
paracetamol treatment in 2/55 (4%). The mean weight of
chloroquine-treated children was 8.5 kg (range 3.2 – 12.0
kg). The mean (median) total dose of chloroquine used
was 34 mg/kg and 25 mg/kg respectively (range 5–110
mg/kg) (figure 1). Only 9/55 (13%) mothers reported
current availability of chloroquine tablets in their house-
hold (median 3 tablets, range 1–10). Most chloroquine
drugs were purchased from local shops and drug sellers.
Discussion
The main finding of this study is a rather low community
effectiveness of chloroquine in the treatment of malaria
episodes among young children in rural Burkina Faso.
Overall, a failure rate of 35% was observed which
declined only marginally to 33% when malaria episodes
in which caretakers did not comply with the advice to give
chloroquine were excluded. This is considerably higher
than the 10% treatment failure rate observed in a study on
chloroquine efficacy in young children of the area [11].
These findings support the hypothesis that treatment effi-
cacy declines drastically under real life conditions in the
community and demonstrate that efficacy trials need to be
complemented with observational studies to assess the
actual health benefits conferred by an intervention [9,16].
The effectiveness of treatment with chloroquine increased
significantly and almost linearly with age, even after con-
trolling for parasite density. The most likely explanation is
a rapid development of immunity within the age range of
our study children, as has been observed in other studies
[1,17,18]. This implies that particular care is needed in the
treatment of the youngest children in whom immunity
will be weakest. Given the fact that the children who par-
ticipated in the study on chloroquine efficacy in the
Table 4: Regression modelling of treatment failure, CQ vs. TRAD group
Model Variables Odds Ratio (95% CI) p-value
1 crude 0.59 (0.33 – 1.06) 0.08
2 age group, sex 0.61 (0.34 – 1.11) 0.10
3 age group, sex, parasite density, diarrhoea 0.64 (0.35 – 1.17) 0.15
4 age group, sex, parasite density, diarrhoea excluding Bwaba ethnicity 0.43 (0.19 – 0.97) 0.04
CQ group: received at least one dose of chloroquine
TRA group: received only traditional treatmentMalaria Journal 2004, 3:36 http://www.malariajournal.com/content/3/1/36
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Nouna area were in the most susceptible age group for
developing clinical malaria (mean age 10 months, range
6–15), the loss of efficacy under community conditions
observed in this study becomes even more pronounced
[11].
Only a small number of episodes were treated solely with
traditional treatment, possibly a consequence of the view
of the local population that western malaria treatment is
more effective than traditional treatment [13]. This may
not apply to all strata of the population, as there was an
interaction between type of treatment and ethnicity.
Moreover, while children receiving traditional treatment
had a higher risk of treatment failure than children treated
with chloroquine after control for age, sex and parasite
density, this association did not reach statistical signifi-
cance until episodes of children belonging to the Bwaba
ethnic group were removed from the analysis. Interest-
ingly, crude failure rates were not higher among cases
from the Bwaba group compared to those belonging to
other ethnic groups. Also these results support the find-
ings from another study in Burkina Faso which has also
shown a lower effectiveness of traditional compared to
modern malaria treatment, traditional treatments are not
identical in different populations [17]. Thus, it may well
be that the traditional treatment used in the Bwaba ethnic
group is more effective against malaria compared to other
traditional treatments in the area. Finally, the observed
significant association of traditional treatment with diar-
rhoea on day 0 may well be a chance finding, given the
lack of a difference between treatment groups in all other
clinical and parasitological parameters.
This study has two limitations. First, information on the
dosage of chloroquine and on the nature of traditional
remedies given to children in the study was lacking. How-
ever, data from the interview survey provide a good esti-
mate of chloroquine dosages used. Although these data
demonstrate a wide variation of chloroquine dosages, it is
reassuring that the reported median dosage complies with
the national recommendations of a total dose of 25 mg/
kg chloroquine for uncomplicated malaria. So why is
there such a difference between efficacy and effectiveness?
The reason may well be a combination of partly chloro-
quine underdosing, poor quality of drugs purchased from
local shops and drug sellers and high frequency of vomit-
ing in febrile young children [19-23]. Moreover, the pos-
sibility of a significant reporting bias during interview
surveys also has to be taken into consideration. Secondly,
a purely clinical definition of treatment failure was used.
Intercurrent febrile illnesses may thus have been misclas-
sified as persisting malaria, thereby overestimating failure
rates. However, this is likely to have only a small effect,
since the fraction of febrile episodes attributable to
malaria (using a highly specific definition) in this cohort
of children was found to be above 50 percent [24].
In conclusion, this study provides clear evidence for a
rather low and age-dependant community effectiveness of
chloroquine in the treatment of P. falciparum malaria in
an area of rural Burkina Faso where the efficacy of chloro-
quine is still sufficiently high in use as first-line treatment.
The observed discrepancy between efficacy and commu-
nity effectiveness implies that many children received
insufficient doses of chloroquine. Our findings thus point
to the importance of (1) better education of parents on
correct dosage of first-line malaria drugs, as well as on
danger signs requiring a visit at a health centre, (2) qual-
ity-control of all malaria drugs used in the community,
and (3) particular care in the treatment of immunologi-
cally naïve very young children. Finally, more studies on
the types and effects of traditional treatments used in dif-
ferent population groups are needed.
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